Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma

Figure 3 Antitumor activity of different drug-loaded nanofilms against human cholangiocarcinoma cells in vitro. A: Effects of different concentrations of prototype gemcitabine and cisplatin on the growth of EGI-1 cells; B: Inhibition of EGI-1 cells caused by different drug-loaded nanofilms with different drug-loading ratios for 30 d; C: Inhibition of EGI-1 cells caused by drug-released media from 10% drug-loaded nanofilms every other week for 30 d; D: Effects of 10% drug-loaded nanofilms on the (a) viability (magnification  × 100); (b) migration (×100); (c) and invasion (×200) of EGI-1 cells; (d) statistical analysis of the proportion of living and dead cells coincubated with different drug-released media; (e) quantitative analysis of the wound closer area following coincubation with different drug-released media; and (f) quantification of migrated cells coincubated with different drug-released media. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs control (n = 6 mice per group). CIS: Cisplatin; GEM: Gemcitabine; PI: Propidium iodide; PLCL: Poly- L-lactide-caprolactone; PLCL-CIS: PLCL nanofilm loaded with CIS; PLCL-GEM: PLCL nanofilm loaded with GEM; PLCL-GC: PLCL nanofilm loaded with both GEM and CIS.